Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)

The National Cancer Institute (NCI) is soliciting grant applications for the development of innovative technologies for cancer research or clinical care. The focus is on early-stage projects that propose proof-of-concept/pilot studies to test the technical feasibility of the proposed method, tool, assay, platform, or instrument. The technologies should offer a high degree of technical innovation and the potential to accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, cancer control, and/or epidemiology. • The proposed technologies may include advanced molecular and cellular analysis platforms, multi-omic and spatial profiling methods, imaging and sensing technologies, immuno-engineering approaches, and innovations in biospecimen processing, modeling, and quality assessment. • The technologies should have potential for widespread applicability but must be focused on cancer applications. • The funding opportunity is part of the NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.